Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional ConstipationBusiness Wire • 09/06/22
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare ConferenceBusiness Wire • 09/01/22
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/04/22
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription DemandBusiness Wire • 08/04/22
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022Business Wire • 05/25/22
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022Business Wire • 05/09/22
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial GuidanceBusiness Wire • 05/05/22
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/28/22
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/17/22
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021Business Wire • 02/17/22
Is Ironwood Pharmaceuticals (IRWD) a Suitable Stock for Value Investors?Zacks Investment Research • 02/10/22
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update CallBusiness Wire • 02/03/22